Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting

Accessibility StatementSkip Navigation The EPIC study will evaluate treatment with IMAAVYâ"¢ versus efgartigimod in adults with gMG and will include a treatment-switch arm The Company also announced new data from the pivotal Vibrance-MG study in which pediatric patients receiving treatment with IMAAVYâ"¢ demonstrated 72 weeks of sustained reduction in immunoglobulin G (IgG), sustained disease control and no new safety concerns IMAAVYâ"¢ is the only FcRn blocker for anti-AChR and anti-MuSK antibody positive ...